Intel's share price moved after Elon Musk publicly referred to discussions around a concept he called "Terafab," linking the initiative to Taiwan Semiconductor Manufacturing Company (TSMC), according to a report from South Korean broadcaster SBS.

The remark, brief as it was, was enough to shift trading in Intel shares. Musk named no signed agreement, disclosed no financial terms and published no timetable. The market reaction followed the mention alone.

What did Musk actually say?

According to the SBS report, Musk spoke of partnership discussions under the label "Terafab" and connected those discussions to TSMC. The term suggests manufacturing infrastructure at an extreme scale — a fabrication plant defined by throughput measured in terabytes or teraflops rather than conventional fab capacity metrics.

That is interpretation, not confirmed fact. Neither Musk, TSMC nor Intel has published a definition of "Terafab" in connection with these discussions. The report itself gives no technical specification, no capital figure and no named counterparties beyond TSMC.

What is confirmed: Musk used the term. He tied it to partnership discussions. He referenced TSMC. Intel's stock responded.

Why does this hit Intel specifically?

The market read Musk's comments through the lens of Intel's current position. Three factors shape that reading:

• Intel remains dependent on external foundries for advanced-node production while it rebuilds its own manufacturing roadmap.
• TSMC fabricates silicon for a customer base that includes the largest AI and automotive players, and capacity negotiations with the Taiwanese foundry move stock prices across the sector.
• Musk controls companies with enormous compute demand, and any procurement signal from him carries weight with traders watching semiconductor supply chains.

Investors appear to have priced in the possibility that Intel participates in — or is excluded from — whatever arrangement the "Terafab" discussions describe. SBS reports only that Intel shares reacted to the mention; it does not state the direction or magnitude of the move in percentage terms.

What remains unverified?

Most of the story. The report contains no confirmation from any of the three companies involved:

• No statement from TSMC acknowledging the discussions.
• No filing or press release from Intel characterizing any potential partnership.
• No comment from Musk's companies on scope, scale or timeline.
• No disclosure of whether "Terafab" refers to a single site, a network of plants or a broader manufacturing concept.

Traders treating the mention as a signal should note the gap between a named concept and a negotiated agreement. Semiconductor partnerships of the scale the term implies typically require multi-year commitments, capital allocation votes and regulatory review in at least two jurisdictions. None of that machinery appears to be in motion publicly.

What happens next?

Watch for confirmations from the companies themselves rather than further market interpretation. A TSMC investor disclosure, an Intel regulatory filing or a concrete statement from Musk would move this from speculation to structured news. Until then, the "Terafab" mention stands as exactly what SBS reported: a remark that shook Intel's share price, with no confirmed substance behind it yet.